The threat of avian influenza A (H5N1). Part III: Antiviral therapy

Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 as well as treatment options are discussed. The third...

Full description

Saved in:
Bibliographic Details
Published in:Medical microbiology and immunology 2007-12, Vol.196 (4), p.203-212
Main Authors: Cinatl, Jr, Jindrich, Michaelis, Martin, Doerr, Hans W
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Animals
Antiviral Agents - therapeutic use
Avian flu
Avian influenza virus
Birds
Drug Therapy, Combination
Epidemiology
Humans
Influenza A Virus, H5N1 Subtype - drug effects
Influenza in Birds - epidemiology
Influenza, Human - drug therapy
Influenza, Human - immunology
Inhibitor drugs
Neuraminidase - antagonists & inhibitors
Pathology
Viral Matrix Proteins - antagonists & inhibitors
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 as well as treatment options are discussed. The third part discusses therapeutic options. Neuraminidase (NA) inhibitors are the most promising agents despite uncertainty about efficacy. Dosage increase, prolonged treatment or combination therapies may increase treatment efficacy and/or inhibit resistance formation. Immune system dysregulation contributes to H5N1 disease. Although current evidence does not support the use of anti-inflammatory drugs beneficial effects cannot be excluded at later disease stages.
ISSN:0300-8584
1432-1831
DOI:10.1007/s00430-007-0048-z